Axcella Health Inc

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative, and liver conditions.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the H.C. Wainwright BioConnect Conference. A webcast of this presentation will be available on the “Investors & News” section of the company's website, www.axcellatx.

Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference

The heavy selling pressure might have exhausted for Axcella Health Inc. (AXLA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 24% in 4 Weeks, Here's Why Axcella Health Inc. (AXLA) Looks Ripe for a Turnaround

Axcella Therapeutics Inc (NASDAQ: AXLA) has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long COVID. Phase 2a evaluates the efficacy and safety of AXA1125 in patients with exertional fatigue related to Long COVID.

Axcella Kickstarts Long COVID Phase 2 Clinical Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, and researchers at the Oxford University Radcliffe Department of Medicine today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Po

Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

Axcella Health Inc. (AXLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Axcella Health Inc. (AXLA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company's executive team. Dr. Koziel, who previously served as Vice President, Clinical Development, joined Axcella in 2019, bringing a

Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA #EMMs--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in the Piper Sandler 33rd Annual Healthcare Conference. A fireside chat from the conference will be made available beginning Monday, November 22 at 10 a.m. ET on the “Investors & News” section of the compan

Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

Casey's General Stores

Lazydays

Owens & Minor

Sunopta

Want to try an out-of-the-box approach? Tap five stocks, namely OMI, STKL, CASY, LAZY and AXLA, with increasing P/E ratios.

5 Winning Stocks Backed by the Overlooked Rising P/E Ratio

Axcella Health (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Axcella Health (AXLA) This Earnings Season?

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “The third quarter of 2021 was a time in which Axcella focused heavily on both execution and expansion,” said Bill Hinshaw, President and Chief Executi

Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 12-15, 2021. These presentations will include further dat

Axcella Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2021

Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last for months following recovery from the infection.

Axcella To Test NASH Candidate In Long COVID Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA #LongCOVID--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced a new clinical program to investigate AXA1125 as a potential treatment for patients with Long COVID, a complex condition also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC). The United Kingdom's Medicines and Healthcare

Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions, today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET. The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcella's management team. Topics will include the company's next clinical program (to

Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference. A live audio webcast of this discussion will be available on the “Investors & News” section of the company's website, www.axcellahealth.com, at 4:30 p.m. ET o

Axcella Announces Upcoming Investor Conference Presentation

Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella (NASDAQ: AXLA) uses endogenous metabolic modulators (EMMs) to treat complex diseases, including liver conditions. One of its leading drug candidates, AXA1665, relies on a pioneering composition of amino acids to offer more comprehensive relief to patients suffering from progressively worsening effects resulting from cirrhosis.

Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation

Image Provided By Pixabay The American Journal of Gastroenterology recently published findings from a clinical study of AXA1125, a groundbreaking potential treatment for nonalcoholic steatohepatitis (NASH) developed by Axcella Health Inc. (NASDAQ: AXLA). The pioneering clinical-stage biotech company has shown the potential to reset multiple targeted biologies that are dysregulated in patients with complex diseases using proprietary combinations of amino acids and metabolites.

Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the publication of results from the company's AXA1125-003 clinical study in The American Journal of Gastroenterology entitled “Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.” Based on the

Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH

Axcella Health's (AXLA) CEO Bill Hinshaw on Q2 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET that morning. The conference call webcast will be available in the Investors & News se

Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021

Arcos Dorados Hlds

Jaguar Health

9 Meters Biopharma

Lantronix

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Blazing Biotechs Highlight Stocks Trading Under $10 With Massive Upside Potential

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the company's multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE). “OHE is a con

Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665

iBio

Tyme Technologies

Looking for biotech penny stocks to watch before Monday? Check these 3 out The post Best Biotech Penny Stocks to Buy?

Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday

The stock price of Axcella Health Inc (NASDAQ: AXLA) increased by over 10% pre-market. This is why it happened.

AXLA Stock Price: Over 10% Increase Pre-Market Explanation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that positive data from the company's AXA1665-002 clinical study were presented last night at the Digestive Disease Week (DDW) 2021 Annual Meeting by Dr. Arun Sanyal, Professor in the Virginia Commonwealth University (VCU) Department of Internal Medicine an

News for Axcella Health Inc Stock (AXLA)